Zobrazeno 1 - 10 of 85 pro vyhledávání: '"Christian Callebaut"'
1
Akademický článek
Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model
Autor: Elena Bekerman, Stephen R. Yant, Laurie VanderVeen, Derek Hansen, Bing Lu, William Rowe, Kelly Wang, Christian Callebaut
Publikováno v: The Journal of Clinical Investigation, Vol 133, Iss 16 (2023)
Long-acting antiretroviral agents for preexposure prophylaxis (PrEP) represent a promising new alternative to daily oral regimens for HIV prevention. Lenacapavir (LEN) is a first-in-class long-acting capsid inhibitor approved for the treatment of HIV
Externí odkaz: https://doaj.org/article/bd05c3d0d12a411f9917bef6f8371399
Zobrazit plný text záznamu
2
Akademický článek
Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trialResearch in context
Autor: Carolina Herrera, Jennifer Serwanga, Laura Else, Lebina Limakatso, Daniel Opoka, Andrew S. Ssemata, Azure-Dee Pillay, Patricia Namubiru, Thabiso B. Seiphetlo, Geoffrey Odoch, Susan Mugaba, Portia Seatlholo, Amara Alieu, Sujan Dilly Penchala, Richard Muhumuza, Berenice Alinde, Stefan Petkov, Kyle O'Hagan, Christian Callebaut, Janet Seeley, Helen Weiss, Saye Khoo, Francesca Chiodi, Clive M. Gray, Pontiano Kaleebu, Emily L. Webb, Neil Martinson, Julie Fox, Nadia Ahmed, Millicent Atujuna, Esther Awino, Linda-Gail Bekker, Mike Chirenje, Janan Dietrich, Jeffrey Dorfman, Clive Gray, Christian Holm Hansen, Stefanie Hornschuh, Ayoub Kakande, Charles Kelly, Mamkiri Khunwane, Limaktso Lebina, Joseph Makhura, Nomvuyo Mangxilana, Freddie Mukasa Kibengo, Gertrude Mutonyi, Lucia Mungate, Winnie Nabukeera, Rehema Nagawa, Phiona Nalubega, Stephen Nash, Denis Ndekezi, Teacler Nematadzira, Lumka Nobula, Jim Rooney, Elzette Rousseau, Eugene Ruzagira, Alison Sango, Ntombexolo Seatlholo, Thabiso Seiphetlo, Robin Shattock, Lynda Stranix-Chibanda, Gugulethu Tshabalala, Emily Webb
Publikováno v: EBioMedicine, Vol 93, Iss , Pp 104648- (2023)
Summary: Background: The efficacy of on-demand HIV pre-exposure prophylaxis (PrEP) for men in sub-Saharan Africa has not been evaluated, and the on-demand PrEP dosing requirement for insertive sex remains unknown. Methods: HIV-negative males 13–24
Externí odkaz: https://doaj.org/article/b5fc6da65f4d414687cac9a3089adfd6
Zobrazit plný text záznamu
3
Akademický článek
Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue
Autor: Laura Else, Sujan D. Penchala, Azure-Dee Pillay, Thabiso B. Seiphetlo, Limakatso Lebina, Christian Callebaut, Suks Minhas, Roland Morley, Tina Rashid, Neil Martinson, Julie Fox, Saye Khoo, Carolina Herrera
Publikováno v: Pharmaceutics, Vol 14, Iss 6, p 1285 (2022)
Background: HIV-1 pre-exposure prophylaxis (PrEP) has focused predominantly on protective efficacy in receptive sex, with limited research on the dosing requirements for insertive sex. We pre-clinically assessed the ex vivo pharmacokinetic–pharmaco
Externí odkaz: https://doaj.org/article/7aa149559dc4428ebae12dd3a114fd4b
Zobrazit plný text záznamu
4
Akademický článek
Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.
Autor: Michael E Abram, Renee R Ram, Nicolas A Margot, Tiffany L Barnes, Kirsten L White, Christian Callebaut, Michael D Miller
Publikováno v: PLoS ONE, Vol 12, Iss 2, p e0172206 (2017)
T97A is an HIV-1 integrase polymorphism associated with integrase strand transfer inhibitor (INSTI) resistance. Using pooled data from 16 clinical studies, we investigated the prevalence of T97A (pre-existing and emergent) and its impact on INSTI sus
Externí odkaz: https://doaj.org/article/4d3f83567e2248c28ddccd47298f8e72
Zobrazit plný text záznamu
5
Akademický článek
Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.
Autor: Christian Callebaut, Yang Liu, Darius Babusis, Adrian Ray, Michael Miller, Kathryn Kitrinos
Publikováno v: PLoS ONE, Vol 12, Iss 2, p e0169948 (2017)
Tenofovir alafenamide (TAF) is a phosphonoamidate prodrug of the nucleotide HIV reverse transcriptase inhibitor tenofovir (TFV). TAF is approved for the treatment of HIV-1 infection as part of the single-tablet regimen containing elvitegravir, cobici
Externí odkaz: https://doaj.org/article/273f4b7ac502475d88dab5f633416e1d
Zobrazit plný text záznamu
8
Lenacapavir: a first-in-class HIV-1 capsid inhibitor
Autor: Hadas, Dvory-Sobol, Naveed, Shaik, Christian, Callebaut, Martin S, Rhee
Publikováno v: Current Opinion in HIV and AIDS. 17:15-21
This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle.Lenacapavir demonstrated picomolar potency in vitro with no c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a83c6574e22d25f93d4c43e5cf038e8
https://doi.org/10.1097/coh.0000000000000713
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje